Harnessing the Power of Oncolytic Viruses: Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article discusses the TILT Biotherapeutics, a Finnish biotechnology company specializing in cancer immunotherapies using oncolytic viruses encoded with cytokines. It mentions that their lead product, TILT-123, is in Phase I clinical trials and has shown promise in targeting and lysing cancer cells while releasing cytokines to activate the immune response. It mentions that the company has attracted investor funding and is competing in the growing field of T-cell-based therapies.